A Phase 2 interventional study of Zoster Vaccine, Live and Comparator: Placebo in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 10th largest by enrollment, is one of 4 that started in 2007, is one of 5 in phase 2, and was the 5th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2007.
This study's enrollment of 309 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2007, is one of 3 in phase 2, and was the 8th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to assess the safety, tolerability, and immunogenicity of ZOSTAVAX™ in patients receiving chronic/maintenance corticosteroids.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants administered ZOSTAVAX™ on Day 1.
Biological: Zoster Vaccine, Live
Participants administered Placebo on Day 1.
Biological: Comparator: Placebo
A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
Also known as: V211
A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
Number of Participants With Serious Adverse Events (SAE)
A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.
Time frame: Up to 182 days postvaccination
Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibodies at 42 Days Postvaccination
The Geometric Mean Titer (GMT) of VZV antibodies in participants' serum samples was assessed by a glycoprotein enzyme-linked immunosorbent assay (gpELISA).
Time frame: 42 days postvaccination
Geometric Mean Fold Rise (GMFR) of the VZV Antibody Response From Day 1 to Day 42 Postvaccination.
The geometric mean fold rise (GMFR) of the VZV antibodies from Day 1 to Week 6 postvaccination.
Time frame: 42 days postvaccination
| Milestone | ZOSTAVAX™ | Placebo |
|---|---|---|
| Started | 207 | 102 |
| Vaccinated | 206 | 100 |
| Completed | 199 | 96 |
| Not completed | 8 | 6 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 |
A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.
| Participants | ZOSTAVAX™ | Placebo |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAE) | 21 | 11 |
The Geometric Mean Titer (GMT) of VZV antibodies in participants' serum samples was assessed by a glycoprotein enzyme-linked immunosorbent assay (gpELISA).
| gpELISA units/mL | ZOSTAVAX™ | Placebo |
|---|---|---|
| Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibodies at 42 Days Postvaccination | 531.1 (453.3 to 622.1) | 224.3 (169.8 to 296.2) |
The geometric mean fold rise (GMFR) of the VZV antibodies from Day 1 to Week 6 postvaccination.
| Ratio | ZOSTAVAX™ | Placebo |
|---|---|---|
| Geometric Mean Fold Rise (GMFR) of the VZV Antibody Response From Day 1 to Day 42 Postvaccination. | 2.3 (2.0 to 2.7) | 1.1 (1.0 to 1.2) |
Collected over Up to 182 days postvaccination for serious adverse events and 42 days postvaccination for other adverse events.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZOSTAVAX™ | — | 21/204 (10.3%) | 43/204 (21.1%) |
| Placebo | — | 11/99 (11.1%) | 10/99 (10.1%) |
| Event | ZOSTAVAX™ | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 7/204 | 2/99 |
| PneumoniaInfections and infestations | 3/204 | 2/99 |
| Cardiac arrestCardiac disorders | 0/204 | 1/99 |
| Hypertensive heart diseaseCardiac disorders | 0/204 | 1/99 |
| GoitreEndocrine disorders | 0/204 | 1/99 |
| Large intestine perforationGastrointestinal disorders | 0/204 | 1/99 |
| Pancreatitis acuteGastrointestinal disorders | 0/204 | 1/99 |
| Cellulitis of male external genital organInfections and infestations | 0/204 | 1/99 |
| Gastritis viralInfections and infestations | 0/204 | 1/99 |
| Scrotal abscessInfections and infestations | 0/204 | 1/99 |
| Event | ZOSTAVAX™ | Placebo |
|---|---|---|
| Injection site erythemaGeneral disorders | 36/204 | 4/99 |
| Injection site swellingGeneral disorders | 23/204 | 5/99 |
| Injection site painGeneral disorders | 22/204 | 8/99 |
| Age, Continuous(years) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| Mean | 69.8 ± 6.9 | 69.9 ± 7.2 | 69.8 ± 7.0 |
| Sex: Female, Male(Participants) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| Female | 140 | 80 | 220 |
| Male | 67 | 22 | 89 |
| Daily Corticosteroid Dose Stratum(Participants) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| 5 to 10 mg of prednisone or equivalent | 182 | 88 | 270 |
| >10 to 20 mg of prednisone or equivalent | 25 | 14 | 39 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Oct 2007, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine